565 related articles for article (PubMed ID: 9635698)
1. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report.
Mate TP; Gottesman JE; Hatton J; Gribble M; Van Hollebeke L
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):525-33. PubMed ID: 9635698
[TBL] [Abstract][Full Text] [Related]
2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
3. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
4. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial.
Stromberg J; Martinez A; Gonzalez J; Edmundson G; Ohanian N; Vicini F; Hollander J; Gustafson G; Spencer W; Yan Di
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):161-71. PubMed ID: 7543891
[TBL] [Abstract][Full Text] [Related]
6. [High-dose rate iridium-192 brachytherapy combined with external beam radiotherapy for localized prostate cancer].
Kasahara K; Inoue K; Karashima T; Inoue Y; Kariya S; Inomata T; Yoshida S; Shuin T
Nihon Hinyokika Gakkai Zasshi; 2001 Jul; 92(5):572-8. PubMed ID: 11517568
[TBL] [Abstract][Full Text] [Related]
7. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
8. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.
Martinez AA; Pataki I; Edmundson G; Sebastian E; Brabbins D; Gustafson G
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):61-9. PubMed ID: 11163498
[TBL] [Abstract][Full Text] [Related]
9. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
10. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
12. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
[TBL] [Abstract][Full Text] [Related]
13. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
14. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
15. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
16. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.
Zelefsky MJ; Hollister T; Raben A; Matthews S; Wallner KE
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1261-6. PubMed ID: 10889379
[TBL] [Abstract][Full Text] [Related]
17. High-dose rate iridium-192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablation.
Chiang PH; Fang FM; Jong WC; Yu TJ; Chuang YC; Wang HJ
Int J Urol; 2004 Mar; 11(3):152-8. PubMed ID: 15009363
[TBL] [Abstract][Full Text] [Related]
18. High-dose rate interstitial with external beam irradiation for localized prostate cancer--results of a prospective trial.
Dinges S; Deger S; Koswig S; Boehmer D; Schnorr D; Wiegel T; Loening SA; Dietel M; Hinkelbein W; Budach V
Radiother Oncol; 1998 Aug; 48(2):197-202. PubMed ID: 9783892
[TBL] [Abstract][Full Text] [Related]
19. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial.
Martinez A; Gonzalez J; Stromberg J; Edmundson G; Plunkett M; Gustafson G; Brown D; Yan D; Vicini F; Brabbins D
Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1019-27. PubMed ID: 7493828
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen spikes after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]